secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZIMMER BIOMET HOLDINGS, INC. (ZBH)
CIK:        0001136869
Form:       8-K
Filed at:   2024-06-20T23:59:59+00:00
Accession:  0000950170-24-075310
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zimmer Biomet appoints Embecta CEO Devdatt Kurdikar to Board of Directors
-------------------------------------------------------------------------

- Board expanded from 10 to 11 members; Devdatt Kurdikar appointed effective June 20, 2024.
- Kurdikar serves as President & CEO of Embecta Corp. (Nasdaq: EMBC), a diabetes management spinoff from BD.
- He will serve on the Corporate Governance Committee and Compensation & Management Development Committee.
- His term expires at the 2025 annual meeting; standard non-employee director compensation applies.
- No arrangements or material interests disclosed; indemnification agreement expected.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1136869/000095017024075310/0000950170-24-075310-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1136869/000095017024075310/zbh-20240620.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-075310

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer